For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Sermorelin
Performance & Musclephase_2_3

Sermorelin

GHRH (1-29)
Performance & Muscle · CAS 86168-78-7
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Performance & Muscle
Evidence grade
B
PubMed records
369
Female-tagged
151
Sex-analysis
1
CAS
86168-78-7
B
Evidence grade B, Phase 2/3 human trial evidence across 369 indexed studies (mixed-sex). How grades work →
Female evidence: Extrapolated
Sermorelin: of 369 PubMed records, 151 are tagged as including female subjects and 1 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Sermorelin is a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH 1-29), the N-terminal fragment that carries the active site responsible for binding the GHRH receptor on pituitary cells. This truncated design retains receptor activity in a compact, research-friendly peptide.

In research models, Sermorelin has been used to study GHRH-receptor signaling, the somatotropic axis, and the pulsatile regulation of growth-hormone release. Investigators examining endocrine feedback and pituitary function have used it as a research material to model how the GHRH pathway governs growth-hormone secretion.

Supplied for in-vitro and laboratory research only, Sermorelin is a useful catalog entry because it represents the GHRH mechanism through its minimal active fragment. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Sermorelin is a synthetic fragment of growth-hormone-releasing hormone (GHRH 1-29) formerly FDA-approved as Geref for assessing growth-hormone deficiency before being discontinued. Human studies exist and have included women, but they focus on the growth-hormone axis rather than female-specific outcomes, and current use is off-label or research.

Evidence in women

Menstrual cycle
Unstudied
Growth-hormone response varies with estrogen status, but sermorelin dosing has not been studied across cycle phases.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data; deliberate GH-axis stimulation in pregnancy has not been evaluated and is not advised.
Hormonal interactions
Unstudied
Estrogen is known to influence the GH/IGF-1 axis, but no controlled sermorelin interaction data exist.
Perimenopause & menopause
Unstudied
No perimenopausal or menopausal efficacy or safety studies.
Sex differences
Unstudied
Women were included in mixed-sex GH studies, but results were not analyzed by sex.

Mechanism

Binds GHRH receptors on the anterior pituitary to stimulate endogenous, pulsatile growth-hormone release.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Historically ~0.2–0.3 mg subcutaneous for GH-deficiency testing (Geref, discontinued); no current standardized therapeutic dose.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: active malignancy (GH-axis stimulation, theoretical)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

injection-site reactionsflushingheadache

Sermorelin reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Sermorelin

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Sermorelin's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Sermorelin?

Sermorelin, also known as GHRH (1-29), is a research compound in our performance muscle category. Sermorelin is a synthetic fragment of growth-hormone-releasing hormone (GHRH 1-29) formerly FDA-approved as Geref for assessing growth-hormone deficiency before being discontinued.

Is Sermorelin studied in women?

Sermorelin: of 369 PubMed records, 151 are tagged as including female subjects and 1 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has Sermorelin been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data; deliberate GH-axis stimulation in pregnancy has not been evaluated and is not advised. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Sermorelin have, and why?

Sermorelin carries evidence grade B. Phase 2/3 human trial evidence across 369 indexed studies (mixed-sex).. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Sermorelin?

No. A female-specific dose for Sermorelin is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Sermorelin administered in research?

In the published literature, Sermorelin is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Sermorelin?

Effects reported in the research literature include injection-site reactions, flushing, headache. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for Sermorelin?

The CAS registry number for Sermorelin is 86168-78-7. It is also referred to as GHRH (1-29), GRF 1-29, Geref. Use it to confirm identity against a Certificate of Analysis.

How should Sermorelin be stored and handled?

Sermorelin sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Sermorelin for research?

For laboratory research use, Sermorelin is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy Sermorelin at Aurevena Research
Research-use supplier: Sermorelin is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

32257855 · 14499707 · 41966639

Related peptides

2X Blend CJC-1295 WO DAC (5mg) / Ipamorelin·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
ACE-031C
ACE-031: of 48 PubMed records, 11 are tagged as including female subjects and 0 carry a sex-analysis tag.
AICARB
AICAR: of 2,496 PubMed records, 329 are tagged as including female subjects and 2 carry a sex-analysis tag.
CJC-1295 with DACC
CJC-1295 with DAC: of 32 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.